| Half-life | 68 hours |
| Tmax | 2.5 h |
| Bioavailability | 37 % (approx) |
| Protein Binding | 7 % |
| Volume of Distribution | 31.1 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | no |
| Notes | Extremely long tissue half-life → short course therapy supported. |
Severity: Moderate
Adverse Effects:
GI upset, QT prolongation, elevated liver enzymes
Contraindications:
Severe hepatic impairment, significant QT prolongation history
Precautions:
Caution with other QT prolonging drugs; avoid in known long QT syndrome